GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Gallbladder and Pancreas/Pleural effusion, acute pancreatitis and Mortality
63

Pleural effusion, acute pancreatitis and Mortality

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2025

Pleural effusion (PE) is a significant clinical finding in patients with acute pancreatitis (AP) and has been shown to be strongly associated with increased severity and mortality in this condition. Here's a detailed explanation of the relationship between pleural effusion, acute pancreatitis, and mortality based on the study findings:

Pleural Effusion and Acute Pancreatitis

  1. Prevalence of Pleural Effusion in AP:
  • In the study, pleural effusion was detected in 20.5% of patients with acute pancreatitis within the first 48 hours of diagnosis using thoracic ultrasound (TUS).
  • The effusions were predominantly anechoic in nature and were classified as moderate in size, with a mean volume of approximately 340 mL on the right side and 310 mL on the left side.
  • Most pleural effusions were unilateral, with 59% appearing on the left side and 41% being bilateral.
  1. Mechanism of Pleural Effusion in AP:
  • Pleural effusion in acute pancreatitis is thought to result from systemic inflammation, increased vascular permeability, and diaphragmatic irritation caused by the inflammatory mediators released during pancreatitis. These processes lead to fluid accumulation in the pleural space.
  1. Ultrasound Findings:
  • Thoracic ultrasound proved to be a reliable bedside imaging tool for detecting pleural effusion early in the disease course, even when effusions were small or moderate in size.
  • Other ultrasound findings, such as atelectasis and B-line patterns, were documented but did not show a significant correlation with mortality like pleural effusion did.

Pleural Effusion and Disease Severity

  1. Correlation with Severe AP:
  • Patients with pleural effusion had a significantly higher prevalence of severe acute pancreatitis (40.9%) compared to those without pleural effusion (2.4%).
  • The presence of pleural effusion was strongly associated with organ dysfunction and systemic involvement, as indicated by higher scores on severity assessment tools like APACHE II, Marshall, and BISAP.
  1. Severity Assessment Scores:
  • The mean Marshall score was higher in patients with pleural effusion (2.0) compared to those without (1.12), reflecting greater organ dysfunction.
  • Similarly, the mean APACHE II score was elevated in patients with pleural effusion (8.36 vs. 5.52), further confirming the association between pleural effusion and severe disease.
  1. Atlanta Classification:
  • Severe acute pancreatitis, as defined by the Atlanta classification, was more frequent among patients with pleural effusion (31.8%) compared to those without (5.9%).
  1. BISAP Score:
  • A BISAP score of ≥3, indicating a higher risk of mortality, was observed in 40.9% of patients with pleural effusion versus only 2.4% of those without.

Pleural Effusion and Mortality

  1. Higher Mortality in Patients with Pleural Effusion:
  • Mortality was significantly higher in patients with pleural effusion (22.7%) compared to those without pleural effusion (3.5%).
  • This highlights pleural effusion as a strong predictor of death in acute pancreatitis.
  1. Independent Predictor of Mortality:
  • Multivariate regression analysis confirmed that pleural effusion was an independent predictor of mortality, with an odds ratio of 6.89 after adjusting for confounders.
  • Additionally, each unit increase in the Marshall score raised the odds of mortality threefold, emphasizing the combined prognostic value of pleural effusion and organ dysfunction scores.
  1. Clinical Implications:
  • Early detection of pleural effusion using thoracic ultrasound can help identify patients at higher risk of severe disease and mortality, enabling timely interventions to improve outcomes.
  • Incorporating pleural effusion findings into the management of acute pancreatitis can enhance risk stratification and guide clinical decision-making.

Advantages of Thoracic Ultrasound for Pleural Effusion Detection

  1. Non-Invasive and Radiation-Free:
  • Thoracic ultrasound is a bedside imaging modality that avoids radiation exposure, making it ideal for critically ill patients.
  1. High Sensitivity:
  • TUS is more sensitive than chest X-rays for detecting small pleural effusions, ensuring early identification of high-risk patients.
  1. Ease of Use:
  • It can be performed rapidly and repeatedly, providing real-time information about pleural abnormalities.

Conclusion

Pleural effusion is a critical marker of severity and mortality in acute pancreatitis. Its presence within the first 48 hours of diagnosis strongly correlates with severe disease outcomes, including organ dysfunction and higher mortality rates. Thoracic ultrasound is a valuable tool for detecting pleural effusion early and should be integrated into diagnostic protocols for acute pancreatitis. By identifying patients at higher risk, clinicians can implement timely interventions to improve survival and recovery outcomes. Future studies should focus on validating these findings in multicenter settings and exploring long-term prognostic implications.

Related Q&A

64

TGF-Beta and Chronic Pancreatitis

TGF-β and Chronic Pancreatitis Transforming Growth Factor-Beta (TGF-β) is a multifunctional cytokine that plays a key role in chronic pancreatitis (CP), particularly in driving fibrosis and disease progression....

65

Fatty Pancreas and PANDORA Hypothesis

The PANDORA Hypothesis (Pancreatic Diseases Originating from Intrapancreatic Fat) is a groundbreaking concept that identifies fat accumulation within the pancreas—referred to as fatty pancreas disease (FPD)—as a common...

66

Native Hawaiian pancreatic cancer disparity study

The study on pancreatic cancer disparities among Native Hawaiians, conducted as part of the Multiethnic Cohort Study, revealed significant findings about the heightened risk faced by this population...

01

Olomorasib Receives FDA Breakthrough Therapy Designation in KRAS G12C–Mutant Pancreatic Cancer: FDA / Oncology Update | August 2026

Introduction: KRAS mutations drive the vast majority of pancreatic cancers, but KRAS G12C represents only about 1–2% of cases. This small molecular subgroup is increasingly actionable. The FDA...

02

A Simple Blood-Based Biomarker (SIRI) Predicts Outcomes in Metastatic Pancreatic Cancer: Pancreatology | August 2026

Introduction: Systemic inflammation plays a major role in pancreatic ductal adenocarcinoma (PDAC), contributing to tumor progression, cachexia, and treatment resistance. The Systemic Inflammation Response Index (SIRI) combines neutrophil,...

03

Higher Dietary Vitamin B6 Intake Is Associated With Lower Gallstone Prevalence: Medicine | August 2026

Introduction: Vitamin B6 participates in cholesterol metabolism, oxidative stress regulation, and inflammatory pathways that may influence gallstone formation. This population-based analysis examined whether dietary vitamin B6 intake is...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer